Thermo Fisher Scientific Inc. (TMO) — Fair Value Analysis

Base-case fair value (P50): $377.60 · Current price: $438.34 · Verdict: Fairly Valued

The Verdict on TMO

Thermo Fisher Scientific (TMO) currently trades at $464.95, but our Monte Carlo simulations suggest a median fair value (P50) of just $396.51. This indicates that TMO is significantly overvalued by -14.7% at its current market price. The rigorous simulation methodology points to a clear disconnect between TMO's present valuation and its intrinsic worth derived from thousands of forward-looking financial scenarios. Investors should note this considerable gap, as the market seems to be pricing TMO well above its statistically probable fair value.

How TMO stacks up against Healthcare

When assessing TMO within the broader Healthcare sector, its operational and financial health registers as "weak" in our quality tier ranking. This fundamental weakness stands in contrast to its current trading price of $464.95. The median fair value of $396.51 reflects this underlying operational profile more accurately than the market price. The -14.7% premium at which TMO trades suggests the market may not be fully accounting for its relative quality tier compared to sector peers, potentially exposing investors to a higher degree of risk given its current valuation.

What this means for investors

For investors considering TMO, the current price of $464.95 presents a notable premium over its median fair value of $396.51, implying a -14.7% downside to fair value. Given TMO's "weak" quality tier relative to the Healthcare sector, this overvaluation suggests caution. While the market may have reasons for its current pricing, our Monte Carlo analysis indicates that the downside scenario is substantial. To understand the full range of potential outcomes, including both bear and bull case scenarios, and to track TMO's fair value as new fundamentals are released, sign up for a free FairCurve account.